All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Coronary artery bypass graft (CABG) has been established as the standard procedure of revascularization for patients with multi-vessel coronary artery disease (CAD). The application of autologous grafts on arteries including internal mammary arteries (IMA), radial arteries (RA), gastroepiploic arteries and inferior epigastric arteries has greatly improved the short- and long-term outcomes of CABG. Compared with saphenous vein grafts (SVGs), arterial grafts have significantly higher graft patency over time. In fact, some authors proposed using total arterial grafts to replace SVGs, although, currently, there is insufficient clinical follow-up data to support this strategy\[[@pone.0203315.ref001]--[@pone.0203315.ref003]\].

One of the challenging issues with arterial grafts is graft spasm leading to intra- and/or post-operative myocardial ischemia and cardiac arrhythmia. While arterial graft spasm was first reported clinically in 1987\[[@pone.0203315.ref004],[@pone.0203315.ref005]\], its mechanisms remain unclear. However, studies have indicated that it is likely multifactorial, including mechanical stimulation from graft manipulation, vasoactive molecules released from activated endothelial cells during cardiac reperfusion, the application of certain vasoactive drugs and so on. These insults cause increased extracellular influx and intracellular sarcoplasmic release of calcium ions through different signaling pathways. A previous meta-analysis indicated that perioperative application of different calcium channel blockers (CCBs) had significant outcome benefits for patients undergoing all types of cardiac surgeries requiring cardiopulmonary bypass (CPB)\[[@pone.0203315.ref005]\]. Topical application of CCBs on isolated IMAs and RAs consistently showed evidence of vasodilatation and increased blood flow\[[@pone.0203315.ref006],[@pone.0203315.ref007]\].

As our understanding of its mechanisms improves, increasing effort has been devoted to developing effective pharmacological interventions for preventing graft spasm after CABG. The most investigated agents for this purpose are CCBs and nitrates. There are also clinical studies for alpha-1 blockers\[[@pone.0203315.ref008]\], phosphodiesterase III inhibitors, e.g. milrinone\[[@pone.0203315.ref009],[@pone.0203315.ref010]\], calcium sensitizers, e.g. levosimendan \[[@pone.0203315.ref011]\], potassium channel openers, e.g. aprikalim\[[@pone.0203315.ref012]\], and prostacyclin analogues, e.g. iloprost\[[@pone.0203315.ref013]\]. These investigational drugs were applied in various ways: topically or intra-graft injection\[[@pone.0203315.ref006],[@pone.0203315.ref014]\], systemically through bolus and/or intravenous (IV) infusion, or mixed in cardioplegia during CPB\[[@pone.0203315.ref015],[@pone.0203315.ref016]\].

Diltiazem (DILT), a benzothiazepine-type CCB, is well known for relieving coronary spasm while uniquely being able to promote vasodilation without rebound tachycardia. Nitroglycerin (NTG) infusion is also one of the first line therapeutic interventions of unstable angina; injection of NTG into IMA grafts showed potent vasodilatation\[[@pone.0203315.ref017]\]. This systematic review and network meta-analysis therefore aims to summarize the available outcome data from clinical trials involving perioperative continuous IV infusion of DILT and/or NTG in patients undergoing on-pump CABG, and compare the drugs' effects on graft blood flow, perioperative mortality, perioperative hemodynamic stability, ventricular functions, postoperative myocardial infarction (MI), new onset cardiac arrhythmias and requirement of inotropic support.

Materials and methods {#sec006}
=====================

Literature search strategy {#sec007}
--------------------------

This systematic review and network meta-analysis was conducted based on the criteria of the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) statement\[[@pone.0203315.ref018]\]. As shown in [Fig 1](#pone.0203315.g001){ref-type="fig"}, a comprehensive literature search was conducted using databases Ovid Medline, PubMed, EMBASE, CINAHL, Google Scholar and Cochrane Central Registry of Controlled Trials. These databases hosted papers published between 1946 and the end of February 2018. The search terms used were: "cardiac surgery", "thoracic surgery", "cardiac surgical procedures", "coronary artery bypass", "cardiopulmonary bypass", "calcium channel blocker", "diltiazem", "nitrates", "nitroglycerin". The detailed search criteria applied in Ovid Medline are shown in [S1 Table](#pone.0203315.s001){ref-type="supplementary-material"}. The included studies should be randomized controlled trials (RCTs) or prospective cohort studies investigating effects of perioperative continuous IV infusion of DILT and/or NTG on arterial graft flow and perioperative outcomes in adult patients undergoing on-pump CABG. The seven reasons for a study to be excluded from final enrollment are: (1) the study is retrospective, (2) the study's subjects were not limited to adult patients, (3) the studied drugs were administered topically, through intra-graft injection or mixed in cardioplegia, (4) the study was of non-cardiac surgeries, off-pump CABG or cardiac surgical procedures necessitating cardiac chamber opening, (5) the study was published as an abstract, a case report, case series, letter to the editor, editorial, narrative or systematic review, meta-analysis, or a study that did not report the investigated outcomes (6) the paper is a duplicated publication of an enrolled study, (7) the study was not approved by an institutional review board.

![PRISMA flowchart.\
The literature search and study enrollment. Flow chart for literature enrollment from identification to final synthesis according to the PRISMA protocol. DILT = diltiazem; NTG = nitroglycerin; RCT = randomized controlled trial.](pone.0203315.g001){#pone.0203315.g001}

The initially-identified studies were screened by one reviewer (XZ) for RCTs or prospective cohort studies. The screened publications were verified by the second reviewer (XY) before being enrolled into the final systematic review and network meta-analysis. We also manually searched through the references of the enrolled papers for potential studies not captured by the database searching strategy.

Data extraction {#sec008}
---------------

Data from enrolled studies were extracted into a spreadsheet by two reviewers (XZ, XY), independently. This data included sample size, geographic regions, age, sex, race/ethnicity and outcomes regarding cardiac functions. Disputations during the process of literature searching and data extraction were resolved upon reaching consensus through discussions with all the co-authors.

The complete texts of the enrolled studies were inspected by the authors independently and the following outcome parameters were extracted: patient characteristics, measurement of arterial graft blood flow, perioperative mortality, incidence of post-operative MI (post-MI), postoperative atrial fibrillation (A-fib), transient cardiac ischemic event (TIE), inotrope requirement, peak postoperative cardiac enzymes and hemodynamic parameters, such as heart rate (HR), cardiac index (CCI), mean blood pressure (mBP) and mean pulmonary arterial pressure (mPAP) and pulmonary artery wedge pressure (PAWP).

The primary outcomes are graft blood flow alteration and perioperative mortality. The remaining perioperative outcomes were further categorized into: (1) cardiac protection outcomes including post-MI, TIE, A-fib and postoperative peak cardiac enzymes. (2) cardiac function outcomes including HR, mBP, mPAP, PAWP and requirement of inotropic support.

Although the results from the individual studies were reported in different formats, the continuous variables were all converted in the data extraction spreadsheet prepared for future meta-analysis, if necessary. The values were converted to mean and standard deviation, the dichotomous variables for frequency of events.

Quality assessment {#sec009}
------------------

The RCTs were evaluated by two reviewers using the Cochrane risk of bias assessment tool\[[@pone.0203315.ref019]\], which evaluated 6 domains including random assignment, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting and other sources of bias. The assessment of "yes," "no," or "unclear" was assigned to each domain for respective designation of a low, high, or unclear risk of bias. If "unclear" or "no" was assigned to one or less domains, the study was evaluated as having a low risk of bias. If over four domains were assigned "unclear" or "no", the study was evaluated as having a moderate risk\[[@pone.0203315.ref020]\], see [Fig 2](#pone.0203315.g002){ref-type="fig"}.

![Quality assessment of enrolled clinical trials.\
Quality assessment was conducted using the Cochrane risk of bias assessment tool. Risk of bias assessment for included studies in meta-analysis was classified as "high", "low" or "unclear".](pone.0203315.g002){#pone.0203315.g002}

Statistical analyses {#sec010}
--------------------

First, the pairwise meta-analyses were conducted for each included outcome using random-effects model. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated for binary outcomes. Mean differences (MDs) and 95% CIs were calculated for continuous outcomes. The pooled OR is considered statistically significant if 95% CI did not contain 1, and the pooled MD is considered statistically significant if 95% CI did not contain 0. Individual and pooled estimates were illustrated using forest plots.

Second, network meta-analysis (NMA) was performed to incorporate multiple comparisons for each available outcome using multivariate meta-analyses, where the within-network heterogeneity was assumed common and the heterogeneity variance was estimated using restricted maximum likelihood (REML). For all three pairwise comparisons (closed triangle loop), both direct and indirect comparisons were integrated to evaluate the effect sizes (ORs, MDs) and 95% CIs. For those outcomes with any two pairwise comparisons available (open triangle loop), indirect estimates for the third pairwise comparison were estimated (ORs, MDs and 95% CIs).

Global test for inconsistency was performed using the Wald test statistic, which follows a chi-squared distribution under the consistency assumption\[[@pone.0203315.ref021]\]. P-value greater than 0.05 indicates no evidence of inconsistency. The rank probability of three treatment effects were computed using the surface under the cumulative ranking curve (SUCRA)\[[@pone.0203315.ref022]\]. Publication bias was evaluated using funnel plots. Sensitivity analysis was conducted by excluding studies with extreme results, defined as larger than twice or smaller than half of the pooled results. All analyses were conducted using Stata 14 (Stata Corp, College Station, TX).

Results {#sec011}
=======

Baseline characteristics for included studies {#sec012}
---------------------------------------------

A total of 1,660 patients were recorded in the 27 included studies. The clinical characteristics are shown in [Table 1](#pone.0203315.t001){ref-type="table"}. Twenty-three trials belonged to two-arm trials, three were in the category of three-arm trials and one was in the category of four-arm trials.

10.1371/journal.pone.0203315.t001

###### Study characters of enrolled clinical trials.

![](pone.0203315.t001){#pone.0203315.t001g}

  Authors, years, journals                      Sample size                          Arterial Grafts   Drug application   Drug dosage                                                                                                                                                                                                                
  --------------------------------------------- ------------------------------------ ----------------- ------------------ ------------- ---- --------------- ----- ------------------------------------ -------------------------------------------- ----------------------------- ----------------------------------------------------------------- ----------------------
  Donegani 1986\[[@pone.0203315.ref023]\]       Thorac cardiovas Surgeon             40                20                 20                 not specified         induction GA                         48 h after releasing aortic cross clamp      IV infusion                   0.5\~3.0 mcg/kg/min                                               0.5 \~1.5 mcg/kg/min
  Hannes 1993\[[@pone.0203315.ref024]\]         Eur J Cardiothorac Surg              91                44                 47                 Yes                   initiation of CPB                    24 h after releasing aortic cross clamp      IV infusion                   0.1 mg/kg/h                                                       1 mcg/kg/min
  Seitelberger 1994\[[@pone.0203315.ref025]\]   J Thorac Cardiovasc Surg             120               60                 60                 Yes                   initiation of CPB                    24h after releasing of aortic cross clamp    IV infusion                   0.1 mg/kg/h                                                       1 mcg/kg/min
  Hannes 1995\[[@pone.0203315.ref026]\]         European Heart Journal               66                31                 33                 Yes                   initiation of CPB                    24 h after releasing aortic cross clamp      IV infusion                   0.1 mg/kg/h                                                       1 mcg/kg/min
  Keilich 1997\[[@pone.0203315.ref027]\]        International Journal of Angiology   211               104                107                Yes                   initiating CPB                       24 h after releasing aortic cross clamp      IV infusion                   0.1 mg/kg/h                                                       1 mcg/kg/min
  Malhotra 1997\[[@pone.0203315.ref028]\]       Eur J Cardiothorac Surg              71                34                 37                 Yes                   initiation of CPB                    24 h after starting drug infusion            IV infusion                   0.1 mg/kg/h                                                       1 mcg/kg/min
  Lischke 1997\[[@pone.0203315.ref029]\]        Anesthetist                          55                29                 26                 not specified         before induction of GA               reach ICU postoperatively                    IV bolus and infusion         0.15 mg/kg, then 3mcg/kg/min                                      1 mcg/kg/min
  Shapira 2000\[[@pone.0203315.ref030]\]        Ann Thorac Surg                      161               77                 84                 Yes                   induction GA                         24h post operatively                         IV infusion, oral             0.1mg/kg/min                                                      0.1 mcg/kg/min
  Lassnigg 2001\[[@pone.0203315.ref031]\]       Wien Klin Wochenschr                 49                24                 25                 Yes                   initiation of CPB                    24 h post op                                 IV infusion                   0.1 mg/kg/h                                                       1 mcg/kg/min
  Hirnle 2000\[[@pone.0203315.ref032]\]         kardiol Pol                          49                24                 25                 Yea                   48 h before CABG                     24 h post op                                 oral and IV infusion          0.1mg/kg/min                                                      1mg/h
  Zhang 2003\[[@pone.0203315.ref033]\]          Natl Med J China                     40                20                 20                 Yes                   initiation of CPB                    24 h after releasing of aortic cross clamp   IV infusion                   0.1 mg/kg/h                                                       1mcg/kg/min
  Tabel 2004\[[@pone.0203315.ref034]\]          Eur J Cardiothorac Surg              60                30                 30                 Yes                   Sternotomy                           after second flow measurement                IV infusion                   0.05\~0.1 mg/kg/h                                                 0.25\~2.5 mcg/kg/min
  Colson 1992\[[@pone.0203315.ref035]\]         J Cardiothorac Vasc Anesth           29                15                               14   not specified         induction of GA                                                                   IV infusion                   2ug/kg/min                                                        
  Zanardo 1993\[[@pone.0203315.ref036]\]        J Cardiothorac Vasc Anesth           24                12                               12   not specified         induction of GA                      24 h post op                                 IV infusion                   2mcg/kg/min                                                       
  Amano 1995\[[@pone.0203315.ref037]\]          Chest                                23                13                               10   not specified         Sternotomy                           not specified                                IV bolus, infusion and oral   0.1 mg/kg bolus, 2 mcg/kg/min until unclamp, then oral 30mg q8h   
  Babin-Ebell 1996\[[@pone.0203315.ref038]\]    Eur J Cardio-thoracic Surg           70                33                               37   Yes                   induction GA                         72h after releasing aortic cross clamp       IV infusion                   0.1 mg/kg/h                                                       
  Yavuz 2002\[[@pone.0203315.ref039]\]          Med Sci Monit                        30                15                               15   Yes                   24 h pre-op                          48 h post op                                 IV infusion                   2 mcg kg/min                                                      
  Fansa 2003\[[@pone.0203315.ref040]\]          Med Sci Monit                        30                15                               15   Yes                   initiation of CPB                    conclusion of CPB                            IV infusion                                                                                     
  Erdem 2015\[[@pone.0203315.ref041]\]          Bra J Cardiovas Surg                 140               70                               70   Yes             yes   induction of GA                                                                   IV infusion                   2.5 mcg/kg/min                                                    
  Thomson 1984\[[@pone.0203315.ref042]\]        Anesthesiology                       20                                   9             11   not specified         before induction of GA               until opening of pericardium                 IV infusion                                                                                     0.5 mcg/kg/min
  Gallagher 1986\[[@pone.0203315.ref043]\]      Anesthesiology                       81                                   41            40   not specified         initiating CPB                       no specified                                 IV infusion                                                                                     1 mcg/kg/min
  Withington 1988\[[@pone.0203315.ref044]\]     European Heart Journal               14                                   7             7    not specified         releasing cross clamp                not specified                                IV infusion                                                                                     1 mcg/kg/min
  Lell et al. 1993\[[@pone.0203315.ref045]\]    J Card Surg                          30                                   20            10   Yes                   Induction of GA                      initiation of CPB                            IV infusion                                                                                     1 or 2 mcg/kg/min
  Knothe 1993\[[@pone.0203315.ref046]\]         Herz                                 30                                   15            15   Yes                   induction of GA                      after releasing aortic cross clamp           IV infusion                                                                                     1.5 mcg/kg/min
  Apostolidou 1999\[[@pone.0203315.ref047]\]    Ann Thorac Surg                      47                                   30            17   Yes                   after releasing aortic cross clamp   24 h post op                                 IV infusion                                                                                     0.5\~1 mcg/kg/min
  Chen 2000\[[@pone.0203315.ref048]\]           Chinese Journal of Surgery           40                                   20            20   not specified         30 mins before induction of GA       24 h post op                                 IV infusion                                                                                     10ug/kg/min
  Zvara 2000\[[@pone.0203315.ref049]\]          J Cardiothorac Vasc Anesth           39                                   20            20   Yes                   induction of GA                      6 h after extubation                         IV infusion                                                                                     2 mcg/kg/min

NMA, network meta-analysis; CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass; GA, general anesthesia; IV, intravenous.

Quality of enrolled studies {#sec013}
---------------------------

Two reviewers (XZ and XY) independently assessed concealment of allocation, blinding, and adequacy of analyses. [Table 2](#pone.0203315.t002){ref-type="table"} presented the quality assessment results using the Cochrane risk of bias assessment tool, with a score ranging from 5 to 7. Note that risk of bias can differ across different outcomes of interest, as each outcome draws from a different subset of studies. To ensure the relative contributions of different sources of direct evidence are accounted for appropriately, we presented risk of bias for each network estimate that integrated pairwise comparisons for primary outcomes. In [Fig 3](#pone.0203315.g003){ref-type="fig"}, the colors represent the risk of bias (green: low, yellow: moderate, red: high).

10.1371/journal.pone.0203315.t002

###### Risk of bias for enrolled studies.

![](pone.0203315.t002){#pone.0203315.t002g}

                      Selection bias                                          Performance bias           Detection bias                                                              Attrition bias                                                         Reporting bias                                                                                 Other bias   
  ------------------- ------------------------------------------------------- -------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ------------ ----------
  Donegani 1986       high risk, prospective non-randomized                   unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Hannes1993          low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Seitelberger 1994   low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Hannes1995          low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Keilich 1997        low risk, \"patients were randomly assingned to ...\"   unclear, did not specify   low risk, the outcome is unlikely to be affected by not complete blinding   low risk, not blind record review, however unlikely to be influenced   low risk                                                                                       low risk     low risk
  Malhotra 1997       low risk \"random assignement...done\"                  unclear, did not specify   low risk, the outcome is unlikely to be affected by not complete blinding   low risk, record review, unlikely to be influenced by not blinding     low risk                                                                                       low risk     low risk
  Lischk 1997         low risk                                                low risk                   low risk, double blinded                                                    low risk, double blinded                                               low risk                                                                                       low risk     low risk
  Hirnle 2000         low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Shapira 2000        low risk, last digit of medical record number           unclear                    low risk                                                                    low risk                                                               low risk, missing data in 16/161, however, long term outcomes not included in meta- analysis   low risk     low risk
  Lassnigg 2001       low risk randomly assigned                              unclear                    low risk                                                                    low risk                                                               unclear, one patient excluded after procedure                                                  low risk     low risk
  Zhang 2003          unclear, randomization done with date of surgery        unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Tabel 2003          low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Colso 1992          low risk                                                low risk                   low risk, double blinded                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Zanardo 1993        low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Armano 1995         low risk                                                low risk                   unclear                                                                     unclear                                                                low risk                                                                                       low risk     low risk
  Babin-Ebell 1996    low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Yavuz 2002          low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Fansa 2003          high risk, prospective non-randomized                   unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Erdem 2015          low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Thomson 1984        low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Gallag 1986         low risk                                                low risk                   low risk, double blinded                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Withington 1988     low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Lell 1993           low risk                                                unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Knothe 1993         low risk                                                low risk                   low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Apostolidou 1999    low risk, computer randomization                        low risk                   low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Chen 2000           unclear                                                 unclear                    low risk                                                                    low risk                                                               low risk                                                                                       low risk     low risk
  Zvara 2000          low risk                                                low risk                   low risk, double blinded                                                    low risk                                                               low risk                                                                                       low risk     low risk

![Network estimate for risk of bias for primary outcomes.](pone.0203315.g003){#pone.0203315.g003}

For primary outcomes of closed-loop or open-loop network estimates, we presented funnel plots comparing any active intervention with non-intervention from pairwise studies. In [Fig 4](#pone.0203315.g004){ref-type="fig"}, we observed there were no indications of asymmetry on funnel plots of the pooled estimates, where different colors represent different pairwise comparisons.

![Funnel plots for primary outcomes.](pone.0203315.g004){#pone.0203315.g004}

Perioperative mortality {#sec014}
-----------------------

Pairwise comparisons did not reveal significant differences in perioperative mortality between patients receiving DILT, NTG or placebo ([Table 3](#pone.0203315.t003){ref-type="table"} and [Fig 5](#pone.0203315.g005){ref-type="fig"}).

10.1371/journal.pone.0203315.t003

###### Pairwise comparison of perioperative outcomes.
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  ------------------------------------------------- ------------------ -------------------------- ---------- -------
  **Pairwise meta-analysis (mortality)**                                                                     
  **Included Studies**                              Comparisons        OR (95% CI)                *I*^*2*^   P
  **7 studies**                                     NTG vs. DILT       0.83 (0.29, 2.41)          0.00%      1.000
  **5 studies**                                     Placebo vs. NTG    1.59 (0.31, 8.28)          0.00%      0.987
  **3 studies**                                     Placebo vs. DILT   4.00 (0.64, 25.15)         0.00%      0.574
  **Pairwise meta-analysis (Cardiac protection)**                                                            
  **Included Studies**                              Comparisons        OR (95% CI)                *I*^*2*^   P
  **post-MI**                                                                                                
  **7 studies**                                     NTG vs. DILT       1.83 (0.77, 4.30)          0.00%      0.975
  **4 studies**                                     Placebo vs. NTG    2.24 (0.80, 6.28)          0.00%      0.596
  **1 studies**                                     Placebo vs. DILT   6.20 (0.27, 141.32)        \-         \-
  **TIE**                                                                                                    
  **5 studies**                                     NTG vs. DILT       1.67(0.99, 2.82)           3.9%       0.384
  **4 studies**                                     Placebo vs. NTG    1.42 (0.73, 2.75)          0.0%       0.707
  **A-fib**                                                                                                  
  **7 studies**                                     NTG vs. DILT       2.67 (1.15, 6.24)          62.20%     0.014
  **2 studies**                                     Placebo vs. DILT   3.00 (1.18, 7.63)          0.0%       0.782
  **Pairwise meta-analysis (Cardiac protection)**                                                            
  **Included Studies**                              Comparisons        MD (95% CI)                *I*^*2*^   P
  **CK**                                                                                                     
  **1 study**                                       NTG vs. Placebo    -36.00 (-232.18, 160.18)   NA         NA
  **5 studies**                                     DILT vs. NTG       -90.29 (-156.79, -23.79)   0.00%      0.691
  **CKMB**                                                                                                   
  **6 studies**                                     DILT vs. NTG       -12.47 (-18.33, -6.61)     63.5%      0.018
  **1 study**                                       DILT vs. Placebo   -1.30 (-7.29,4.69)         NA         NA
  **Trop-T**                                                                                                 
  **4 Studies**                                     DILT vs. NTG       -0.66 (-0.87, -0.44)       0.0%       0.42
  **Pairwise meta-analysis (Cardiac function)**                                                              
  **Included Studies**                              Comparisons        OR (95% CI)                *I*^*2*^   P
  **Inotrope**                                                                                               
  **4 studies**                                     NTG vs. DILT       1.78 (0.78, 4.07)          26.1%      0.255
  **2 studies**                                     Placebo vs. DILT   0.19 (0.04, 0.73)          0.0%       0.419
  **Pairwise meta-analysis (Cardiac function)**                                                              
  **Included Studies**                              Comparisons        MD (95% CI)                *I*^*2*^   P
  **CCI**                                                                                                    
  **5 studies**                                     DILT vs. NTG       -0.02 (-0.18, 0.13)        21.3%      0.279
  **2 studies**                                     NTG vs. Placebo    0.16 (-0.98, 0.42)         69.2%      0.072
  **1 study**                                       DILT vs. Placebo   -0.10 (-0.62, 0.42)        NA         NA
  **HR**                                                                                                     
  **5 studies**                                     NTG vs. Placebo    2.54 (-6.22, 11.29)        95.1%      0.00
  **1 study**                                       DILT vs. NTG       -13.00 (-23.56, -2.45)     NA         NA
  **1 study**                                       DILT vs. Placebo   -9.40 (-18.88, 0.08)       NA         NA
  **mBP (mmHg)**                                                                                             
  **3 studies**                                     NTG vs. Placebo    -2.61 (-11.70, 6.48)       98.30%     0.00
  **1 study**                                       DILT vs. NTG       2.00 (-7.92, 11.92)        NA         NA
  **1 study**                                       DILT vs. Placebo   1.90 (-8.54, 12.34)        NA         NA
  **mPAP (mmHg)**                                                                                            
  **2 studies**                                     NTG vs. Placebo    -2.29 (-4.81, 0.23)        29.40%     0.23
  **1 study**                                       DILT vs. NTG       -1.00 (-3.04, 1.04)        NA         NA
  **PAWP (mmHg)**                                                                                            
  **4 studies**                                     NTG vs. Placebo    -1.05 (-1.43, -0.70)       0.0%       0.64
  **1 study**                                       DILT vs. NTG       -0.50 (-2.97, 1.97)        NA         NA
  **1 study**                                       DILT vs. Placebo   0.80 (-1.84, 3.44)         NA         NA
  ------------------------------------------------- ------------------ -------------------------- ---------- -------

Note: OR greater than 1 favor the first treatment.

![Perioperative mortality.\
Forest plot of OR of perioperative mortality. The differences among the interventions are statistically insignificant.](pone.0203315.g005){#pone.0203315.g005}

The network meta-analysis for mortality between two treatment groups and one placebo group ([Table 4](#pone.0203315.t004){ref-type="table"}) implied that DILT, NTG and placebo were comparable when integrating the direct and indirect comparison results, where no inconsistency was detected (global test for inconsistency indicated *p* = 0.39). However, the SUCRA values implied that NTG and DILT were comparable, but better than placebo in preventing perioperative mortality ([Table 5](#pone.0203315.t005){ref-type="table"}).

10.1371/journal.pone.0203315.t004

###### Network meta-analysis results for mortality, post MI, TIE, A-fib, and inotrope.
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  ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------
  **Network meta-analysis (mortality), no inconsistency (*p***[\*\*](#t004fn003){ref-type="table-fn"} = **0.39)**                                                                                                                        
  **OR (95%CI)**                                                                                                    **Placebo**                                                **DILT**                                                  **NTG**
  **Placebo (vs.)**                                                                                                 \-                                                         1.42 (0.39, 5.22)                                         1.37 (0.40, 4.64)
  **DILT (vs.)**                                                                                                    0.70 (0.19, 2.57)                                          \-                                                        0.96 (0.35, 2.64)
  **NTG (vs.)**                                                                                                     0.73 (0.22, 2.47)                                          1.04 (0.38, 2.81)                                         \-
  **Network meta-analysis (post-MI), no inconsistency (*p***[\*\*](#t004fn003){ref-type="table-fn"} = **0.99)**                                                                                                                          
  **OR (95%CI)**                                                                                                    **Placebo**                                                **DILT**                                                  **NTG**
  **Placebo (vs.)**                                                                                                 \-                                                         4.51 (1.34, 15.25)                                        2.26 (0.85, 5.99)
  **DILT (vs.)**                                                                                                    0.22 (0.07, 0.75)                                          \-                                                        0.50 (0.20, 1.24)
  **NTG (vs.)**                                                                                                     0.44 (0.17, 1.18)                                          2.00 (0.80, 4.96)                                         \-
  **Network meta-analysis (TIE), no inconsistency (*p***[\*\*](#t004fn003){ref-type="table-fn"} = **0.93)**                                                                                                                              
  **OR (95%CI)**                                                                                                    **Placebo**                                                **DILT**                                                  **NTG**
  **Placebo (vs.)**                                                                                                 \-                                                         2.21 (0.94, 5.21) [\*](#t004fn002){ref-type="table-fn"}   1.43 (0.73, 2.77)
  **DILT (vs.)**                                                                                                    0.45 (0.19, 1.07) [\*](#t004fn002){ref-type="table-fn"}    \-                                                        0.64 (0.38, 1.11)
  **NTG (vs.)**                                                                                                     0.70 (0.36, 1.36)                                          1.55 (0.90, 2.66)                                         \-
  **Network meta-analysis (A-fib), no inconsistency (*p***[\*\*](#t004fn003){ref-type="table-fn"} = **0.46)**                                                                                                                            
  **OR (95%CI)**                                                                                                    **Placebo**                                                **DILT**                                                  **NTG**
  **Placebo (vs.)**                                                                                                 \-                                                         2.86 (0.65, 12.61)                                        1.10 (0.20, 5.97) [\*](#t004fn002){ref-type="table-fn"}
  **DILT (vs.)**                                                                                                    0.35 (0.08, 1.55)                                          \-                                                        0.39 (0.18, 0.85)
  **NTG (vs.)**                                                                                                     0.91 (0.17, 4.88) [\*](#t004fn002){ref-type="table-fn"}    2.58 (1.18, 5.67)                                         \-
  **Network meta-analysis (Inotrope), no inconsistency (*p***[\*\*](#t004fn003){ref-type="table-fn"} = **0.14)**                                                                                                                         
  **OR (95%CI)**                                                                                                    **Placebo**                                                **DILT**                                                  **NTG**
  **Placebo (vs.)**                                                                                                 \-                                                         0.51 (0.16, 1.61)                                         0.28 (0.06, 1.21) [\*](#t004fn002){ref-type="table-fn"}
  **DILT (vs.)**                                                                                                    1.95 (0.62, 6.11)                                          \-                                                        0.55 (0.21, 1.41)
  **NTG (vs.)**                                                                                                     3.57 (0.82, 15.51) [\*](#t004fn002){ref-type="table-fn"}   1.83 (0.71, 4.72)                                         \-
  ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------

vs.: row versus column. OR less than 1 favor the treatment specified in the row; OR greater than 1 favor the treatment specified in the column;

\*: indirect comparison;

\*\*: p-value from global test for inconsistency.

10.1371/journal.pone.0203315.t005

###### SUCRA scores for network meta-analysis.

![](pone.0203315.t005){#pone.0203315.t005g}

  SUCRA score (%)   DILT    NTG    Placebo
  ----------------- ------- ------ ---------
  **Mortality**     65.0    68.6   16.4
  **Post-MI**       94.4    52.8   2.8
  **TIE**           94.8    46.1   9.1
  **A-fib**         95.2    27.5   27.2
  **Inotrope**      45.5    5.8    98.6
  **CCI**           51.3    27.3   71.4
  **HR**            97.0    11.8   41.2
  **mPAP**          76.9    54.5   18.5
  **PAWP**          46.4    87.3   16.3
  **CK**            93.4    31.8   24.7
  **CKMB**          77.9    3.5    68.6
  **Trop-T**        100.0   0.0    NA
  **mBP**           35.6    75.0   39.4

Note: the scores are inversely related to the frequencies of complications or the values of continuous variables.

Cardiac protection outcomes {#sec015}
---------------------------

Four trials reported arterial graft flow measurements, but the data were insufficient for synthesis. One study revealed that, compared to placebo, continuous perioperative IV infusion of DILT significantly increased IMA blood flow\[[@pone.0203315.ref041]\]. Results from two other studies showed that patients receiving NTG had significantly higher blood flow in IMA or radial grafts\[[@pone.0203315.ref050],[@pone.0203315.ref051]\], while a study comparing DILT to NTG showed that patients in the DILT group had significantly higher IMA blood flow\[[@pone.0203315.ref034]\].

From the NMA, post-MI had a closed triangle loop with no inconsistency (global test for inconsistency indicated *p* = 0.99). Although pairwise meta-analysis results for post-MI were not significant ([Fig 6](#pone.0203315.g006){ref-type="fig"}), network meta-analysis results revealed that, compared to DILT, placebo had higher rates of post-MI (OR = 4.51, 95% CI: 1.34 to 15.25) ([Table 4](#pone.0203315.t004){ref-type="table"}).

![Postoperative MI.\
Forest plot of OR of postoperative MI. There was no significant difference in pairwise comparison between placebo and NTG, placebo and DILT, NTG and DILT.](pone.0203315.g006){#pone.0203315.g006}

Pairwise meta-analysis results showed that patients who received NTG (OR = 2.67, 95% CI: 1.15 to 6.24) and placebo (OR = 3.00, 95% CI: 1.18 to 7.63) had higher rates of postoperative A-fib than those who received DILT ([Table 2](#pone.0203315.t002){ref-type="table"} and [Fig 7](#pone.0203315.g007){ref-type="fig"}).

![Postoperative A-fib.\
Forest plot of OR of postoperative A-fib. DILT had significantly lower odds than NTG and placebo.](pone.0203315.g007){#pone.0203315.g007}

Since post-MI had a closed triangle loop with no inconsistency, we presented the network meta-analysis results by integrating direct and indirect evidence. For open triangle sloops (TIE, A-fib) with no inconsistency (global test for inconsistency indicated *p* = 0.93, *p* = 0.46, respectively), we presented both the direct estimates from conventional meta-analyses and the indirect estimates from network meta-analyses (Tables [4](#pone.0203315.t004){ref-type="table"} and [5](#pone.0203315.t005){ref-type="table"}). From the NMA, TIE and A-fib had an open triangle loop with no inconsistency. Based exclusively on indirect comparisons ([Table 4](#pone.0203315.t004){ref-type="table"}), placebo had a higher but statistically insignificant rate of TIE than DILT ([Fig 8](#pone.0203315.g008){ref-type="fig"}), while NTG had a significantly higher rate of A-fib ([Fig 7](#pone.0203315.g007){ref-type="fig"}) than DILT (OR = 2.58, 95% CI: 1.18 to 5.67).

![Postoperative TIE.\
Forest plot of OR of postoperative TIE. There was no statistically significant difference between placebo and NTG, NTG and DILT.](pone.0203315.g008){#pone.0203315.g008}

The SUCRA values indicated that DILT ranked the highest in terms of protecting the heart from post-MI, TIE and A-fib (94.4%, 94.8%, 95.2%, respectively) ([Table 5](#pone.0203315.t005){ref-type="table"}). The network meta-analysis results were consistent with the pairwise comparisons. The ranking from highest to lowest odds of post-MI, TIE and A-fib is placebo\>NTG\>DILT.

In addition, we observed that patients who received NTG also had higher post-operative peak cardiac enzymes: CK (MD = 90.29, 95% CI: 23.79 to 156.79), CKMB (MD = 12.47, 95% CI: 6.61 to 18.33) and Troponin (MD = 0.66, 95% CI: 0.44 to 0.87) than DILT ([Table 2](#pone.0203315.t002){ref-type="table"}).

Cardiac function outcomes {#sec016}
-------------------------

In pairwise meta-analyses, patients treated with DILT had significantly lower post-operative HR than those with NTG (MD = 13, 95% CI: -23.56 to -2.45). Patients who received placebo had lower PAWP compared with NTG (MD = -1.05, 95% CI: -1.43 to -0.70). Compared with DILT, patients who received placebo had lower odds of requiring postoperative inotrope support (OR = 0.19, 95% CI: 0.04 to 0.73). Among the interventions, there was no significant difference in CCI or mBP ([Table 2](#pone.0203315.t002){ref-type="table"} and [Fig 9](#pone.0203315.g009){ref-type="fig"}). Based exclusively on indirect comparisons with no inconsistency, we observed that NTG patients needed more inotropic support compared to placebo as well, although the result was not significant. The SUCRA score ranking from highest to lowest indicated rates of needing inotropic support is NTG\> DILT\>placebo ([Table 5](#pone.0203315.t005){ref-type="table"}).

![Requirement of postoperative inotropic support.\
Forest plot of OR of postoperative inotropic support between placebo and DILT, NTG and DILT. Patients who received DILT had significantly higher odds of needing inotropic support compared to those who received placebo.](pone.0203315.g009){#pone.0203315.g009}

Discussion {#sec017}
==========

To summarize the results of our current conventional and network meta-analyses, intraoperative measurements indicated that both DILT and NTG increased graft blood flow, which may help preventing graft spasm. However, the data are insufficient for synthesis. Compared with placebo, patients who received perioperative continuous IV infusion of DILT had significantly lower odds of postoperative cardiac ischemia and A-fib, but patients on DILT may need more inotropic support compared to placebo. Compared with NTG, the significantly lower HR and postoperative peak cardiac enzymes in patients on DILT indicates that DILT may be superior to NTG in preventing postoperative cardiac ischemic injuries.

The goal of CABG is to restore blood supply to ischemic heart through arterial and venous grafts. Graft spasm during and early after the procedure has negative impacts on the cardiac function and hemodynamic stability. CCBs and nitrates are two major categories of coronary vasodilators that were investigated for preventing graft spasm. Among the CCBs, DILT, a benzothiazepine, and verapamil, a phenylalkylamine, were considered suitable for perioperative continuous IV infusion due to their negative chronotropic effect. Studies *in vitro* and *in vivo* have consistently demonstrated that CCBs, topically applied or directly injected into the grafts, can significantly increase blood flow in human IMA and the radial artery (RA) grafts. Data from studies by Erdem\[[@pone.0203315.ref041]\] and Tabel\[[@pone.0203315.ref034]\] showed that continuous IV infusion of DILT is superior to both placebo and NTG in improving blood flow in dissected left IMA and RA segments before graft anastomosis. Although there were no data of direct flow measurement postoperatively, the lower incidence of cardiac ischemia and cardiac arrhythmia from the current meta-analysis indicated that coronary blood flow was likely better maintained early postoperatively in patients who received perioperative DILT infusion.

Our meta-analysis showed that intraoperative infusion of DILT resulted in significantly lower odds of postoperative A-fib. This is particularly interesting as the most recent ACCF/AHA guideline for CABG in 2011 states that nondihydropyridine CCBs such as DILT can be useful to control the ventricular rate in the setting of A-fib but are not indicated for prophylaxis\[[@pone.0203315.ref052]\]. However, this recommendation was based on one meta-analysis published in 1991\[[@pone.0203315.ref053]\]. In that study, verapamil, a nondihydropyridine CCB, failed to show a protective effect against the development of supraventricular arrhythmias (SVAs) after CABG. The discrepancy between that meta-analysis and ours may be due to the differential efficacy of oral verapamil and intravenous DILT against SVAs and the significant improvements to surgical and perioperative managements over the years. The results from our meta-analysis suggest that DILT might be useful for prophylaxis against A-fib after CABG.

The mechanism of cardiac protection by DILT is likely multifactorial. DILT inactivates cell surface L-type calcium channels, preventing the extracellular influx and sarcoplasmic release of calcium ions, promoting smooth muscle relaxation and therefore dilation of native and grafted coronary vessels\[[@pone.0203315.ref054]\]. Additionally, experimental data suggest that DILT could be involved in regulating endothelial function. DILT reduces the blood concentration of endothelin-1, a potent vasoconstrictor released from vascular endothelium, which may promote vascular smooth muscle relaxation through nitric oxide (NO) related signaling pathways\[[@pone.0203315.ref055],[@pone.0203315.ref056]\]. In fact, there is evidence suggesting DILT could up-regulate NO synthase gene expression in endothelial cells\[[@pone.0203315.ref057]\]. Besides increasing blood supply through dilating coronary vessels, DILT may also have significant anti-inflammatory effects by regulating pro- and anti-inflammatory cytokines\[[@pone.0203315.ref040],[@pone.0203315.ref058]\]. Clinically, Haak et al.\[[@pone.0203315.ref059]\] found that endothelin-1 level in circulation was elevated during and immediately after CABG, and perioperative DILT IV infusion significantly reduced endothelin-1 release. Compared to those who received NTG, patients who received DILT had more favorable hemodynamic status early postoperatively.

Nitrate family molecules, including NTG, have been applied clinically to relieve acute and chronic angina pectoris since 1876. Its mechanism was found to be NO mediated vasodilation of coronary arteries to improve oxygen supply to ischemic cardiac muscle, and afterload reduction to decrease oxygen demanding from the heart\[[@pone.0203315.ref060]--[@pone.0203315.ref062]\]. Previous studies confirmed that topical application and intravascular injection of NTG had potent vasodilatory properties\[[@pone.0203315.ref063]\]. However, despite their effectiveness in relieving acute chest pain, the long-term outcome benefit of nitrates in patients with CAD remains questionable. It is well documented that patients continuously taking nitrates quickly develop significant tolerance to the drugs, which not only diminish the treatment effects, but also had the tendency of causing more cardiac ischemic events\[[@pone.0203315.ref064]\]. Nakamura et al.\[[@pone.0203315.ref065]\], found that chronic usage of nitrates in patients with CAD may be associated with increased mortality. A large-scale retrospective study showed that pre-operative IV infusion of NTG failed to provide short term outcome benefits in patients who underwent CABG for unstable angina, patients on preoperative NTG also required prolonged postoperative mechanical ventilation and had more acute cardiovascular events\[[@pone.0203315.ref066]\]. The results from the current meta-analysis also suggest that perioperative continuous IV infusion of NTG had less cardiac protective effects in patients undergoing CABG compared to DILT; patients receiving NTG are more likely to have cardiac arrhythmic events compared to placebo and DILT. Therefore, perioperative continuous IV infusion of NTG may not be beneficial for patients having CABG.

In this study, network meta-analysis was used to compare treatment effectiveness of three treatment groups. The results suggest that DILT has the best protective effects against cardiac ischemia and arrhythmia in patients undergoing on-pump CABG. The advantage of network meta-analysis, an extension of traditional pairwise meta-analysis, is that it has the advantage of comparing multiple treatments with few or no head-to-head comparison data available. It can also help to determine the best available treatment and provide clinical guidelines. By "recycling" the data from prior studies, network meta-analysis is a cost-efficient statistical tool for comparing multiple interventions.

The current systematic review and network meta-analysis has some limitations, however: Firstly, due to the heterogeneity in the designs of the original studies, many critical outcomes cannot be evaluated because of unavailable or insufficient published data. Secondly, the sample sizes in most of the enrolled studies are relatively small, as we did not enroll unpublished data. This limitation in the quantity and quality of data could affect the power of the pairwise and network meta-analyses. Thirdly, the studied population in the enrolled studies were elective patients whose clinical conditions were relatively stable. Clinically more complicated, unstable patients were mostly excluded before or during the studies. This may be a confounding factor for the analyses of perioperative mortality, as it suggests that the conclusions drawn from the current meta-analysis may not apply to patients with different severities of clinical conditions. Most importantly, the studies enrolled were from the last three decades, an extensive period that has seen significant improvements in surgical techniques, perioperative and long-term medical managements of the patients undergoing on- or off-pump CABG. Studies have shown significant reduction of mortality as well as improvement of short- and long-term outcomes\[[@pone.0203315.ref067],[@pone.0203315.ref068]\]. Due to the unavailability of anatomical evidence supporting the relief of graft spasm after closing of sternum as well as insufficient long-term follow-up data of DILT and NTG applied perioperatively, the overall outcome benefits of perioperative continuous IV infusion of DILT and/or NTG in patients undergoing on-pump CABG remains uncertain.

In conclusion, the current systematic review and network meta-analysis suggests that, compared to NTG and placebo, perioperative continuous IV infusion of DILT had stronger protective effects against postoperative ischemic cardiac injuries and A-fib. Possibly, DILT's outcome benefits may be due to increased blood flow in arterial grafts. However, compared to placebo, patients may need more inotropic support.
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